Sanofi (SNY)
(Delayed Data from NSDQ)
$56.33 USD
+0.22 (0.39%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $56.32 -0.01 (-0.02%) 6:36 PM ET
3-Hold of 5 3
A Value C Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$56.33 USD
+0.22 (0.39%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $56.32 -0.01 (-0.02%) 6:36 PM ET
3-Hold of 5 3
A Value C Growth C Momentum A VGM
Zacks News
Is Artificial Intelligence the Next Big Thing in Biotech?
by Kinjel Shah
Artificial intelligence can drastically reduce the time taken to develop new life-saving drugs.
Pharma/Biotech Stocks to Watch This Prostate Cancer Month
by Zacks Equity Research
Here we highlight a few companies that are focused on developing treatments for prostate cancer.
Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars
by Zacks Equity Research
Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.
Regeneron/Sanofi's sBLA for Praluent to be Reviewed by FDA
by Zacks Equity Research
The FDA will review Regeneron (REGN) and Sanofi's sBLA for its PCSK9 Inhibitor Praluent to reduce risk of major adverse cardiovascular events.
Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus
by Zacks Equity Research
Novartis (NVS) to sell parts of its Sandoz Unit. AstraZeneca (AZN), Merck (MRK), Pfizer (PFE) and others announce pipeline and regulatory updates.
Alnylam's Shares Up as Onpattro Gets FDA and EU Approvals
by Zacks Equity Research
Shares of Alnylam (ALNY) increase due to the FDA and European approval for Onpattro.
Sanofi's Blood Disorder Drug Cablivi Gets Approval in Europe
by Zacks Equity Research
Sanofi's (SNY) Cablivi receives approval for the treatment of acquired thrombotic thrombocytopenic purpura, a rare blood clotting disorder.
Alnylam Gets European Nod for First-Ever RNAi Therapeutic
by Zacks Equity Research
Alnylam's (ALNY) Onpattro, the first ever RNA interference (RNAi) therapeutic, has been granted marketing authorization by the European Commission.
The Zacks Analyst Blog Highlights: Visa, PNC, SAP, Sanofi and Ross
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Visa, PNC, SAP, Sanofi and Ross
Emergent (EBS) to Buy Narcan Maker Adapt Pharma for $735M
by Zacks Equity Research
Emergent (EBS) inks a deal to buy Adapt Pharma. This move will add the latter's popular Narcan nasal spray to its portfolio.
Top Research Reports for Visa, PNC Financial & SAP
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa (V), PNC Financial Services Group (PNC) and SAP SE (SAP)
Zai Lab Stock Down, Atopic Dermatitis Candidate Trial Fails
by Zacks Equity Research
Shares of Zai Lab (ZLAB) decline following the failure of a phase IIA study on its pipeline candidate, ZL-3101, for the treatment of atopic dermatitis.
Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio
by Kinjel Shah
The large-cap pharma industry is on track to recovery. Here are two stocks from the space that investors may consider betting on.
Regeneron's Eylea Gets FDA Nod for Wet AMD as a 12-Week Dose
by Zacks Equity Research
Regeneron Pharmaceuticals (REGN) gets the FDA approval for the label expansion of its lead drug, Eylea as a treatment for wet AMD with a modified 12-week dosing schedule.
Regeneron, Teva Announce Positive Data on Osteoarthritis Drug
by Zacks Equity Research
Regeneron (REGN) along with partner Teva announces positive top-line results from a late-stage candidate on fasinumab in patients with chronic pain from osteoarthritis of the knee or hip.
Medtronic Unveils Inner CircleSM Program, Boosts Diabetes Arm
by Zacks Equity Research
Medtronic (MDT) focuses on initiatives to boost its diabetes business.
Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD
by Zacks Equity Research
Regeneron (REGN) suffers setback as the FDA issues a CRL to its application for label expansion of Eylea for wet AMD with a modified 12-week dosing schedule.
Alnylam (ALNY) Gets FDA Nod for First-Ever RNAi Therapeutic
by Zacks Equity Research
Alnylam (ALNY) receives FDA approval for Onpattro to treat polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold
by Zacks Equity Research
Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.
Roche's (RHHBY) Xolair Gets Breakthrough Therapy Status
by Zacks Equity Research
Genentech's, a subsidiary of Roche (RHHBY), allergy drug, Xolair, gets Breakthrough Therapy designation in the United States for the prevention of severe food allergic reactions.
Alnylam's (ALNY) Q2 Loss Wider Than Expected, Sales Beat
by Zacks Equity Research
Alnylam (ALNY) posted wider-than-expected loss in the second quarter of 2018 and received a positive opinion from the CHMP for the marketing authorization of patisiran.
Emergent (EBS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) rides high on earnings as well as revenue beat in Q2.
The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis
Pharma Stock Roundup: PFE Dominates Headlines, BMY Drug Gets EU Approval
by Zacks Equity Research
Pfizer (PFE) reports strong second-quarter results. European Commission approves Pfizer and Bristol-Myers' (BMY) medicines.
BioMarin (BMRN) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
BioMarin (BMRN) reports mixed second-quarter results with earnings missing estimates but sales beating the same.